SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Year: 2019
Type: article
Study design: Clinical Trial
Source: Journal of Thoracic Oncology
Authors: Charu Aggarwal, Mary W. Redman, Primo N. Lara, Hossein Borghaei, Philip Hoffman, Jeffrey D. Bradley, Alfred J. Newman, Marvin J. Feldman, Katherine Minichiello, Jieling Miao, Philip C. Mack, Vassiliki A. Papadimitrakopoulou, Roy S. Herbst, Karen Kelly, David R. Gandara
Institutions: University of Pennsylvania, Fred Hutch Cancer Center, UC Davis Comprehensive Cancer Center, Fox Chase Cancer Center, University of Chicago, Washington University Medical Center, Novant Health Presbyterian Medical Center, Sinai Hospital, The University of Texas MD Anderson Cancer Center, Yale Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1000381934, G1044130170, G1065259983, Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO), G1266999854, G1548551769, ECOG-ACRIN Network Group Operations Center, G1938688226, G2061465891, G2117393317, G2406815399, G3270693678, G332150848, G3647597407, SWOG Network Group Operations Center of the NCTN, G3748303287, G4289044101, NRG Oncology Network Group Operations Center, G4768247927, G5645591806, G5671623325, G594289469, G629255163, Lead Academic Participating Site for the Development and Conduct of NCTN Trials, G6880957883, G6970698343, Yale Cancer Center NCTN, G7451701487, G7852806821, G8526228613, G860041726, NCORP of the Carolinas (Greenville Health System NCORP), Alliance for Clinical Trials in Oncology Operations Center, G8852283793, Yale Clinical and Translational Science Award
OpenAlex ID: W2952562570